SCHEMBL20069807

SCHEMBL20069807

COc1ccc(CN2C3CC2CN(C(C)C)C3)cc1Cn1cccn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.57
KMT2A Q03164 6/20 0.49
LMNA P02545 4/20 0.49
MEN1 O00255 5/20 0.49
ALDH1A1 P00352 3/20 0.49
RET P07949 1/20 0.48
NPSR1 Q6W5P4 3/20 0.48
HTT P42858 3/20 0.48
GAA P10253 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
MAPT P10636 4/20 0.43
SIGMAR1 Q99720 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
USP2 O75604 1/20 0.36
PDE4B Q07343 1/20 0.36
MC4R P32245 1/20 0.36
KAT7 O95251 3/20 0.35
KAT6B Q8WYB5 3/20 0.35
KAT6A Q92794 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22031236 0.89 L3MBTL1 (0.53) L3MBTL1KMT2ALMNAMEN1ALDH1A1
SCHEMBL22031238 0.88 L3MBTL1 (0.54) L3MBTL1KMT2ALMNAMEN1ALDH1A1
SCHEMBL21159098 0.79 L3MBTL1 (0.42) L3MBTL1KMT2ALMNAMEN1ALDH1A1
SCHEMBL10066968 0.77 KMT2A (0.56) L3MBTL1KMT2ALMNAMEN1ALDH1A1
SCHEMBL20071140 0.76 SIGMAR1 (0.50) KMT2AMEN1ALDH1A1RETNPSR1
SCHEMBL20071139 0.76 SIGMAR1 (0.50) LMNAALDH1A1RETHTTTDP1
SCHEMBL4345848 0.74 KMT2A (0.54) L3MBTL1KMT2ALMNAMEN1ALDH1A1
SCHEMBL10022368 0.72 L3MBTL1 (0.49) L3MBTL1KMT2ALMNAMEN1ALDH1A1
SCHEMBL20069809 0.70 ALDH1A1 (0.48) KMT2ALMNAMEN1ALDH1A1MAPT
SCHEMBL10053919 0.70 MEN1 (0.50) L3MBTL1KMT2ALMNAMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2024-02-29 US disclosed
US-20210186959-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2021-06-24 US disclosed
EP-3753939-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS Array Biopharma Inc. (US) 2020-12-23 EP disclosed
US-10172851-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
WO-2018071447-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF L3MBTL1 1445/4885KMT2A 1171/4885LMNA 2631/4885
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF L3MBTL1 1445/4885KMT2A 1171/4885LMNA 2631/4885
US-20210186959-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF L3MBTL1 1445/4885KMT2A 1171/4885LMNA 2631/4885
US-10172851-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF L3MBTL1 1445/4885KMT2A 1171/4885LMNA 2631/4885
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF L3MBTL1 1445/4885KMT2A 1171/4885LMNA 2631/4885
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF L3MBTL1 1445/4885KMT2A 1171/4885LMNA 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.